WX  WuXi PharmaTech (Cayman) Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.045 (+0.098%)

Growth Price

Overvalued by 69.77%

Stability Price

Overvalued by 81.68%

Company Metrics

  • P/E 40.98
  • P/S 4.19
  • P/B 3.61
  • EPS 1.12
  • Cash ROIC 18.76%
  • Cash Ratio 1.16
  • Dividend 0 / 0%
  • Avg. Vol. 610,668.00
  • Shares 71.02M
  • Market Cap. 3.26B

Company Description

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, primarily engages in providing laboratory and manufacturing services to support research and development for pharmaceutical, biotechnology, and medical device companies. It operates in two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers various services for pharmaceutical companies, which incl... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Johnson & Johnson, WuXi PharmaTech (Cayman) Inc. (ADR): Aging Chinese ...
ETF Daily News - Nov 17, 2014
investing George Leong: China is dealing with an aging population. By 2030, the number of Chinese citizens 65 years or older is estimated to come in at a whopping 240 million, or about 18% of the current population.
The State Of Chinese Company Take-Private Offers: A Look At WuXi PharmaTech
Benzinga - Nov 19, 2015
While nothing would look particularly interesting from a run-of-the-mill press release, diving deeper into WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE: WX) SEC filings provide more insight into a conflicted buyout attempt led by Chairman and CEO Ge Li, ...
Hedge Funds Aren't Crazy About WuXi PharmaTech (Cayman) Inc. (ADR) (WX) Anymore
Insider Monkey (blog) - Jun 6, 2013
Is WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) ready to rally soon? Prominent investors are taking a pessimistic view.
WuXi PharmaTech (WX) Stock Gains on Buyout Offer
TheStreet.com - Aug 14, 2015
"We rate WUXI PHARMATECH (CAYMAN)-ADR (WX) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we ...
These Are Apex Capital's Top Biotech Stock Picks
Insider Monkey (blog) - Oct 28, 2015
Apex's holding of WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) was boosted by 4% during the third quarter, with the fund reporting ownership of 1.72 million shares, a position valued at $74.4 million at the end of September.
Jefferies Boosts Targets Across Pharmaceutical Service Stocks
Benzinga - May 27, 2015
Analysts David Windley and Sean Dodge surveyed 60 R&D decision-makers who expected “their outsourced budgets to grow in the high-teens, which would be the highest since 2005-2007,” when CRO P/E valuations were approximately 25x versus 20x ...
Do Hedge Funds and Insiders Love Alere Inc (ALR)?
Insider Monkey (blog) - Aug 26, 2013
We'll check out the relationship between both of these indicators in other stocks similar to Alere Inc (NYSE:ALR). These stocks are PerkinElmer, Inc. (NYSE:PKI), WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX), PAREXEL International Corporation ...
Is Royal Gold, Inc USA) (RGLD) A Good Stock To Buy?
Insider Monkey (blog) - Dec 2, 2015
At the end of this article, we will also compare Royal Gold, Inc USA) (NASDAQ:RGLD) to other stocks, including WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX), MPLX LP (NYSE:MPLX), and American Eagle Outfitters (NYSE:AEO) to get a better sense of ...
China Stock Roundup: JD, Tencent to Invest $1.55B in Bitauto, Alibaba Pays ...
Zacks.com - Jan 15, 2015
(1 ADR= 1 share). Around $750 million worth of resources and $400 million cash will be provided by JD.com. Meanwhile, Tencent is buying shares worth $150 million.
Is Genomic Health, Inc. (GHDX) A Good Stock To Buy?
Insider Monkey (blog) - Dec 15, 2016
Investing in hedge funds can bring large profits, but it's not for everybody, since hedge funds are available only for high-net-worth individuals.